Back to top

Analyst Blog

Q4 Revenue Guidance Revised Upwards

Brian Marckx, CFA

Corgenix Medical (CONX) announced on 7/3/12 that fiscal Q4 (ending 6/30/12) revenue is expected to be approximately $2.3MM, or about $170k (8%) higher than previously anticipated.  $2.3MM in Q4 will push fiscal 2012 revenue to almost $9.3MM, up 17% from 2011.  While not specifically stated in the press release, the implication is that the upward revenue revision may relate to stronger than expected contract manufacturing revenue in Q4.  Contract manufacturing has been the single biggest catalyst of CONX's revenue growth through the first nine months of fiscal 2012 (compared to the same period in 2011), contributing more than one-half of the 25% growth over that period.

Specifically related to CONX's contract manufacturing business, in June the company announced a five year manufacturing and supply agreement with diaDexus.  Under the deal, Corgenix will manufacture and supply the PLAC test, a cardiovascular assay that measures LP-PLA2, a marker which recently got an endorsement from the American Association of Clinical Endocrinologists when they added it to their recommended list of tests for heart disease.    

Prior to the revised revenue guidance we were modeling Q4 and FY2012 revenue of $2.16MM and $9.12MM, we've now moved our numbers to $2.33MM and $9.29MM.  Our Q4 and FY2012 EPS estimates remain unchanged (-$0.00, -$0.01).  We have also made no material adjustments to the remainder of our model. 

We are maintaining our Outperform rating and $0.50 price target on CONX.     

Please visit to access a complimentary copy of the full CONX research report.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.55 +11.64%
CHINA BIOLO… CBPO 55.57 +7.40%
BITAUTO HOL… BITA 96.14 +5.58%
LUXOFT HOLD… LXFT 38.77 +3.64%
INSITE VISI… INSV 0.30 +3.41%